title: Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.
authors: Elizabeth
authors: E
authors: Phillips
authors: John A
authors: JA
authors: Bartlett
authors: Ian
authors: I
authors: Sanne
authors: Michael M
authors: MM
authors: Lederman
authors: John
authors: J
authors: Hinkle
authors: Franck
authors: F
authors: Rousseau
authors: David
authors: D
authors: Dunn
authors: Rebecca
authors: R
authors: Pavlos
authors: Ian
authors: I
authors: James
authors: Simon A
authors: SA
authors: Mallal
authors: David W
authors: DW
authors: Haas
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D001219:Aspartate Aminotransferases / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000235:genetics*; D065702:Cytochrome P-450 CYP2B6; D004311:Double-Blind Method; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy*; D015235:HLA-B Antigens / Q000235:genetics*; D059811:HLA-DRB1 Chains / Q000235:genetics; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D019829:Nevirapine / Q000009:adverse effects* / Q000627:therapeutic use; D010089:Oxidoreductases, N-Demethylating / Q000235:genetics; D010641:Phenotype; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D013019:South Africa
chemical_list: D019380:Anti-HIV Agents; D015235:HLA-B Antigens; C500126:HLA-B*58:01 antigen; D059811:HLA-DRB1 Chains; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; D001189:Aryl Hydrocarbon Hydroxylases; C585599:CYP2B6 protein, human; D065702:Cytochrome P-450 CYP2B6; D010089:Oxidoreductases, N-Demethylating; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase